CERVICAL SQUAMOUS CELL CARCINOMA
Clinical trials for CERVICAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cancer drug enters human testing for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in people testing a new drug called EVOLVE104 for advanced bladder cancer and several types of advanced squamous cell cancers. It aims to find a safe and effective dose for patients whose cancer has continued to grow despite standard treatments. The study …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Apr 03, 2026 22:47 UTC
-
New cancer drug targets specific protein in advanced tumors
Disease control Recruiting nowThis early-stage trial is testing a new drug called ALE.P03 in adults with advanced or spreading cancers that have a specific protein marker (CLDN1+). The study aims to find a safe and effective dose and see if the drug can shrink tumors. It will enroll 180 patients with cancers …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New 'Smart Bomb' drug targets tough cancers in major trial
Disease control Recruiting nowThis study is testing a new experimental drug called ALE.P02 for adults with advanced squamous cell cancers that have spread or can't be removed by surgery. The drug is designed to target cancer cells that have a specific marker called Claudin-1. Researchers will first find the s…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC